Free Trial
NASDAQ:PDSB

PDS Biotechnology Q1 2024 Earnings Report

PDS Biotechnology logo
$1.19 +0.04 (+3.48%)
Closing price 08/22/2025 04:00 PM Eastern
Extended Trading
$1.18 0.00 (-0.42%)
As of 08/22/2025 07:02 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

PDS Biotechnology EPS Results

Actual EPS
-$0.30
Consensus EPS
-$0.37
Beat/Miss
Beat by +$0.07
One Year Ago EPS
N/A

PDS Biotechnology Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

PDS Biotechnology Announcement Details

Quarter
Q1 2024
Time
N/A
Conference Call Date
Wednesday, May 15, 2024
Conference Call Time
7:00AM ET

Upcoming Earnings

PDS Biotechnology's Q3 2025 earnings is scheduled for Thursday, November 13, 2025, with a conference call scheduled at 8:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

PDS Biotechnology Earnings Headlines

HC Wainwright Issues Positive Estimate for PDSB Earnings
Missed the Last 10,000% Surge? Here’s Your Next Chance
Axcelis Technologies went from $2.50 to $180—a staggering 7,100% return. These are the kinds of small-cap breakouts Fierce Analyst aims to catch before they go mainstream. Our research team uses data and trend analysis to uncover high-potential stocks early. And now, you can get free alerts on the next set of breakout candidates—before the crowd rushes in.tc pixel
See More PDS Biotechnology Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like PDS Biotechnology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on PDS Biotechnology and other key companies, straight to your email.

About PDS Biotechnology

PDS Biotechnology (NASDAQ:PDSB), a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma alternate reading framed protein (TARP) for treating prostate and breast cancers; and PDS0103 for ovarian, colorectal, lung, and breast cancers. In addition, the company is developing PDS01ADC, a novel investigational Interleukin 12 fused antibody-drug conjugate that enhances the proliferation, potency, and longevity of T cells in the tumor microenvironment; and PDS0104, a novel investigational Tyrosinase-related Protein 2 targeted immunotherapy that stimulates a potent targeted T cell attack against melanoma. Further, the company provides PDS0202, a novel investigational influenza vaccine that generates broad and robust antibody and T cell responses that provide protection against continually evolving strains of seasonal flu and potentially emerging pandemic flu. It has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. The company was founded in 2005 and is based in Princeton, New Jersey.

View PDS Biotechnology Profile

More Earnings Resources from MarketBeat